X

Xiamen Amoytop Biotech Co Ltd
SSE:688278

Watchlist Manager
Xiamen Amoytop Biotech Co Ltd
SSE:688278
Watchlist
Price: 72.05 CNY 1.61% Market Closed
Market Cap: 29.3B CNY
Have any thoughts about
Xiamen Amoytop Biotech Co Ltd?
Write Note

Xiamen Amoytop Biotech Co Ltd
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Xiamen Amoytop Biotech Co Ltd
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
X
Xiamen Amoytop Biotech Co Ltd
SSE:688278
Accrued Liabilities
ÂĄ243.7m
CAGR 3-Years
70%
CAGR 5-Years
51%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Accrued Liabilities
ÂĄ2.6B
CAGR 3-Years
49%
CAGR 5-Years
55%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Accrued Liabilities
ÂĄ1.1B
CAGR 3-Years
8%
CAGR 5-Years
18%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Accrued Liabilities
ÂĄ268.5m
CAGR 3-Years
37%
CAGR 5-Years
39%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Accrued Liabilities
ÂĄ325.2m
CAGR 3-Years
-8%
CAGR 5-Years
85%
CAGR 10-Years
60%
Imeik Technology Development Co Ltd
SZSE:300896
Accrued Liabilities
ÂĄ116.1m
CAGR 3-Years
52%
CAGR 5-Years
49%
CAGR 10-Years
N/A
No Stocks Found

Xiamen Amoytop Biotech Co Ltd
Glance View

Market Cap
29.3B CNY
Industry
Biotechnology

Xiamen Amoytop Biotech Co., Ltd., nestled in the heart of China's coastal city Xiamen, unfolds its narrative as a dynamic player in the biotechnology and healthcare industries. Born from an environment brimming with innovation, the company has diligently carved its niche by focusing on the research, development, and commercialization of diagnostic reagents and test kits. Its core competency lies in crafting solutions designed for precision and reliability, addressing the ever-evolving needs of laboratories and healthcare providers. Through a blend of cutting-edge technology and a keen understanding of biological complexities, Xiamen Amoytop has established itself as a reliable partner, providing essential tools that drive accurate diagnostics and improve patient outcomes across the globe. The company generates revenue by designing and delivering an extensive array of diagnostic products that are indispensable to modern medical practices. From infectious disease diagnostics to blood-based tests, Xiamen Amoytop leverages advancements in molecular biology to offer products that elevate the standards of health diagnostics. By supplying these critical products, the company ensures a steady flow of income sourced from healthcare facilities, research institutions, and diagnostic laboratories both domestically and internationally. Through its robust distribution network and focus on quality assurance, the company continues to expand its market presence, translating its technological prowess into financial growth and global impact.

Intrinsic Value
100.22 CNY
Undervaluation 28%
Intrinsic Value
Price
X

See Also

What is Xiamen Amoytop Biotech Co Ltd's Accrued Liabilities?
Accrued Liabilities
243.7m CNY

Based on the financial report for Dec 31, 2023, Xiamen Amoytop Biotech Co Ltd's Accrued Liabilities amounts to 243.7m CNY.

What is Xiamen Amoytop Biotech Co Ltd's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
51%

Over the last year, the Accrued Liabilities growth was 115%. The average annual Accrued Liabilities growth rates for Xiamen Amoytop Biotech Co Ltd have been 70% over the past three years , 51% over the past five years .

Back to Top